论文部分内容阅读
目的探讨生长抑素联合乌司他丁治疗急性重症胰腺炎的临床效果。方法选取医院2012年6月-2014年6月收治的重症胰腺炎患者200例。根据患者的自愿原则分为生长抑素治疗对照组和生长抑素联合乌司他丁治疗的试验组,2组各100例。观察2组患者的临床疗效、不良反应发生情况及腹内压。结果试验组患者的总有效率为95.00%高于对照组的67.00%,差异有统计学意义(P<0.05)。试验组患者的不良反应发生率为4.00%低于对照组的34.00%,差别有统计学意义(P<0.05)。试验组患者的腹内压为(4.35±2.40)mmHg低于对照组的(9.10±4.30)mmHg,差异有统计学意义(P<0.05)。结论生长抑素联合乌司他丁治疗急性重症胰腺炎可有效减轻患者的痛苦,促进患者痊愈。
Objective To investigate the clinical effect of somatostatin combined with ulinastatin in the treatment of acute severe pancreatitis. Methods 200 cases of severe pancreatitis admitted to the hospital from June 2012 to June 2014 were selected. According to the principle of voluntary patients divided into somatostatin treatment group and somatostatin combined with ulinastatin treatment group, two groups of 100 cases. The clinical efficacy, the incidence of adverse reactions and intra-abdominal pressure in the two groups were observed. Results The total effective rate of the experimental group was 95.00% higher than 67.00% of the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the test group was 4.00% lower than 34.00% in the control group, the difference was statistically significant (P <0.05). The intra-abdominal pressure (4.35 ± 2.40) mmHg in the test group was lower than that in the control group (9.10 ± 4.30) mmHg, with significant difference (P <0.05). Conclusion Somatostatin combined with ulinastatin in the treatment of acute severe pancreatitis can effectively alleviate the suffering of patients and promote the recovery of patients.